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SUMMARY
Background. As patellar tendinopathies are frequently chronic there has been plenty of 
research carried out to develop effective treatments, among which platelet-rich plasma (PRP) 
and hyaluronic acid (HA). 
Hypothesis. Therefore we aimed to compare the effect after three months following injec-
tions of PRP compared with HA injections on patients with a proximal patellar tendinopathy.
Methods. 33 sportsmen with chronic proximal patellar tendinopathies were included and 
randomised into 2 groups and treated respectively with PRP (obtained using an apheresis 
machine) or HA injections. To assess the evolution of the pathology, algo-functional tests 
(VISA-P and IKDC) and isokinetic tests were carried out pre-injection, after 6 weeks and 
after 3 months post-injections.
Results. The results of VAS, algometric scores, IKDC scores and VISA-P showed a consider-
able improvement in the two groups over time (p<0.01), except for the US findings. Isokinetic 
tests showed significant modifications for the quadriceps in C60 (p=0.01) for the pathological 
limb only at the end of the follow-up period. VAS associated with isokinetic tests decreased 
significantly for all contraction modes after three months in the HA group (p<0.05). Correla-
tions showed that there was a significant negative association between VAS and strength in 
C60, C240 and E30 (p<0.01) only for the PRP group. 
Conclusion. Both PRP and HA can alleviate the symptoms of proximal patellar tendinopa-
thy in the medium term. However, only PRP leads to a decrease in pain associated with an 
increase in the strength of the quadriceps.
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INTRODUCTION
Patellar tendinopathies are particularly frequent in various 
sports, especially where athletes perform many jumps/land-
ings as in volleyball, basketball or the triple jump, etc. (1) Its 
treatment can be difficult and the condition often remains 
chronic (2). This is the reason why new treatments have 
been developed, among which feature platelet-rich plas-
ma (PRP) injections (3). Some clinical tests have previously 
evaluated the effect of one or multiple PRP injections in the 
treatment of proximal patellar tendinopathies (4-7). Even 
if there exists a lack of general agreement concerning its 
preparation and use, and that recent systematic reviews are 
controversial, some of these have concluded that PRP could 
be appropriate as a treatment in such indications (8-12). 
Recently, the anti-inflammatory and viscoelastic properties of 
hyaluronic acid (HA) on liquid connective tissue have been 
suggested for the treatment of tendinopathies (13). Some 
fundamental studies show encouraging results concerning HA’s 
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ability to promote tendon gliding and reduce adhesion as well 
as to improve the tendon’s architectural organisation (14-16). 
Some observations also support its use in a clinical environ-
ment to diminish pain and improve function (17, 18). More-
over, some tests with patients suffering from various tendinop-
athies have demonstrated that HA injections can lead to better 
clinical results than with corticosteroid injections (19-21).
We aimed to compare the effect of PRP versus HA injec-
tions after three months on patients who have a proximal 
patellar tendinopathy.
METHODS
All experimental procedures and protocols used in this 
investigation were reviewed and approved by the Ethics 
Committee of our University. Our protocol (PRP collec-
tion and injection, rehabilitation post-injection, assessments 
during the follow-up) has been described previously (22-24).
Our study was registered as clinical trial 2010-021957-38 
(amended) by the “Agence Fédérale des Médicaments et 
des Produits de Santé” (AFMPS) in Belgium. The authors 
confirm that all ongoing and related trials for this interven-
tion are registered.
A power calculation was carried out to determine the ideal 
number of subjects required to observe a statistically signif-
icant difference in the VAS scale compared with previous 
studies. This showed that, with 10 subjects per group, a 
power of 80% at the 5% critical level, and a standard devi-
ation of 2.5 if such a difference exists, would be suitable. 
Thirty-three patients (all male), with chronic (more than 3 
months) proximal patellar tendinopathy, diagnosed clinical-
ly and confirmed by ultrasound scans (US) and/or magnet-
ic resonance imaging (MRI), without bone conflict or bone 
edema, were enrolled and randomized into 2 groups (PRP 
or HA) from 1 October 2015 to 30 June 2017 (Figure 1). 
One criterion for inclusion was for patients to have had 
an unresponsive experience with other classical conser-
vative treatments (painkillers, NSAIDs or physiotherapy, 
including eccentric rehabilitation and shock wave therapy). 
They were fully randomised into two groups (PRP and HA 
respectively), having first signed an informed consent form. 
Complete assessments were made for each subject using the 
same timing and a variety of scores: 10-Point Visual Analog 
Scale (VAS); Clinical examination using a pressure Algom-
eter Commander (JTech Medical Industries, Salt Lake City, 
Utah); International Knee Documentation Committee form 
(IKDC); Victorian Institute of Sport Assessment—Patellar 
questionnaire (VISA-P); Isokinetic assessment, performed 
using a Cybex Norm (Cybex International, Medway, Massa-
chusetts, USA) after a 10-min warm-up on a cycle ergome-
ter. The modalities evaluated were concentric 60°s−1 (C60) 
and 240°s−1 (C240), and eccentric 30°s−1 (E30) on both 
quadriceps. A VAS score was used to quantify pain resulting 
from each test; US (Logiq S7, GE Healthcare, Chicago, Illi-
nois). A complete evaluation was made before the infiltra-
tions, and then repeated by the same examiner at an interval 
of 6 weeks and 3 months after the last injection. 
Before platelets were collected, a haematological cell count 
for each patient was performed under laboratory condi-
tions. PRP was obtained using an apheresis machine (COM.
TEC and kit CS5L, Fresenius-Kabi, Bad-Homburg, Germa-
ny) (25). We decided to collect platelets with a concentra-
tion of around 8.5x105 platelets/microL (almost no leuko-
cytes or erythrocytes). Immediately prior to infiltration, 
300 microL of CaCl2 were added to the PRP to activate the 
platelets. Six milliliters of PRP were injected once only into 
the patellar tendon of subjects of group 1 after disinfection. 
Only one perforation in the hypo-echoic area of the tendon 
was carried out under US guidance (24). Local anaesthetic 
was not used in order to avoid a decrease in platelet activity 
linked to a pH modification (26). 
The subjects in group 2 received two peri-tendinous HA 
2% (40mg/2mL, Ostenil Tendon, TRB Chemedica Interna-
tional SA, Geneva, Switzerland) injections of 2 mL under 
US guidance at one week apart (19, 21). No local anaesthet-
ic was used as for group 1.
Patients in both groups were given local cryotherapy imme-
diately following the infiltration. In case of pain, they were 
forbidden any anti-inflammatory drugs, but allowed to use 
type I or II classical pain killers. 
After 5 to 7 days of relative rest, patients commenced a 
standardised progressive sub-maximal eccentric program, 
consisting of 5 sessions of 15 repetitions 3 times a week and 
supervised by a physiotherapist (27). This eccentric exer-
cise was carried out using the weight of the patient’s body, 
with the back against the wall. The patient would slowly 
slide his back down the wall until his pathologic leg bent 
to a 60° angle before pushing on both legs to return to the 
starting position. A thirty second rest period was allowed 
between sessions. The patient was also treated with electro-
stimulation, stretching of the quadriceps, and cryotherapy. 
After one week of rehabilitation, a second infiltration of 2 
mL of HA was administered to the subjects in Group 2, 
following the same protocol. Five to seven days after the 
second infiltration, the sub-maximal eccentric protocol was 
again commenced for another 5 week period (supervised 
by a physiotherapist). The angulation and the number of 
sessions were both progressively increased during the reha-
bilitation, from 60° to 90° and from 5 to 7 sessions of 15 
to 20 repetitions, respectively. Ten minutes of cycloergom-
eter exercise, using low resistance, was also added to the 
program 2 weeks after the second treatment, and proprio-
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ception exercises were introduced after 1 month. No sport-
ing activities were authorised before 6 weeks after the injec-
tion. After this period, a progressive and sports-specific 
training was restarted under medical supervision with the 
aim of returning completely to the sport after 3 months.
Results were expressed as the mean ± standard deviation of 
the mean (SD). Normality was investigated by comparing 
the mean and median, by plotting histogram and QQ-plot. 
The Shapiro-Wilk test was also performed. At time 0, the 
two groups were compared using a Student’s t-test for inde-
pendent samples. Evolution over time for both groups was 
studied using generalised linear mixed models (GLMM). 
The association between quantitative parameters was tested 
using the Pearson’s (r) or Spearman’s correlation (rs) coef-
ficient or asymmetric distributions. A coefficient > 0 indi-
cates an increasing relationship between variables, a coef-
ficient < 0 a decreasing relationship. Correlations less than 
0.3 were considered as negligible, between 0.3 and 0.5 as 
low, between 0.5 and 0.7 as moderate and greater than 0.7 as 
high. Results were considered significant at a level of uncer-
tainty of 5% (p < 0.05). Statistical analyses were conducted 
using Statistical Analysis System version 9.4 software (SAS 
Institute, Cary, North Carolina).
RESULTS
Eighteen subjects (group 1: aged 29.5±9.9 years; 78.9±12.8kg; 
177.4±6.9cm) received a 6-milliliter intra-tendinous leuko-
cyte-poor PRP injection (obtained using an aphaeresis 
machine) (25) under US guidance. The other fifteen subjects 
(group 2: aged 29.3±8.1 years; 77.1±10.6kg; 178.1±5.8cm) 
received two peri-tendinous HA 2% (40mg/2mL) injections 
(2mL) under US guidance one week apart. 
At baseline, no significant differences were observed 
between the 2 groups except for algometer results in favour 
of the PRP group (p=0.019).
Fourteen out of 18 subjects (77,8%) in the PRP group 
and 11 out of 15 subjects (73,3%) in the HA group were 
responders to the treatments (decrease of pain >50%).
The results of VAS (p<0.01), algometric scores (p<0.01), 
IKDC scores (p<0.01) and VISA-P (p<0.01) showed a 
considerable improvement in the two groups with time 
(Figure 1), except for the US findings. For group 1 (Table 
I), isokinetic tests showed significant modifications for the 
quadriceps with an improvement of maximum peak torque 
in C60 (p=0.01) for the pathological limb at the end of 
follow-up. For group 2, the improvement of quadriceps 
maximum peak torque at C240°/s was significant (p<0.01) 
for the pathological knee only 6 weeks post injections. In 
this group, VAS associated with isokinetic tests decreased 
significantly for all contraction modes after three months of 
the study.
Correlations showed that there was a significant negative 
association between VAS and strength in C60 (r =-0.66, p = 
0.0030), C240 (r =-0.56, p = 0.016), and E30 (rs =-0.66, p = 
0.0030) only for the PRP group but these associations were 
moderate There was no significant association between the 
VAS score and strength for the HA group (p > 0.05).






• Not meeting inclusion criteria (n=4)
• Declined to participate (n=12)
• Other reasons (n=1)
Assessed for eligibility (n=50)
HA injection (n=15)PRP injection (n=18)
Analysis (n=18)Analysis (n=18)
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Table I.  Results for the isokinetic assessment for both groups at the 3 monitoring points. Quad C60 or C240: Quadriceps 
concentric 60°/s or 240°/s; Quad E30: Quadriceps eccentric 30°/s*; p <0.05 between T0 and T2**; p <0.05 between T0 and 
T3***; p <0.05 between T2 and T3.  T0: before injection; T1: 6 weeks after injection; T2: 3 months after injection.
Group 1  T0 T1 T2
 (mean ± SD) (mean ± SD) (mean ± SD)
Quad C60 (N.m) 167.11 ± 49.12 167.27 ± 48.96 159.38 ± 46.42***        
VAS C60 2.63 ± 2.92 1.69 ± 1.87 2.00 ± 1.79
Quad C240 (N.m) 114.33 ± 30.91 114.38 ± 34.98 115.94 ± 33.12
VAS C240 2.00 ± 2.77 1.44 ± 2.02 1.11 ± 1.03
Quad E30 (N.m) 170.94 ± 88.17 191.83 ± 76.07 192.66 ± 77.45
VAS E30 4.66 ± 3.47 2.97 ± 2.49 3.33 ± 2.42
 Group 2 T0 T1 T2
(mean ± SD) (mean ± SD) (mean ± SD)
Quad C60 (N.m) 163.33 ± 39.95 157.06 ± 35.27 161.40 ± 36.72
VAS C60 3.93 ± 2.57 2.90 ± 2.46 2.33 ± 2.49**
Quad C240 (N.m) 98.33 ± 21.26 108.73 ± 20.70* 107.66 ± 21.46
VAS C240 3.53 ± 2.35 1.33 ± 1.58* 1.06 ± 1.48**
Quad E30 (N.m) 190.66 ± 44.81 189.86 ± 41.49 199.60 ± 47.41
VAS E30 5.66 ± 2.46 4.13 ± 2.79* 3.66 ± 3.13**
Figure 2. Results for the VAS, algometer and algo-functional scores (VISA-P and IKDC) for both groups at the 3 monitoring 
points. All the graphs show a significant improvement over time (p<0.01).
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DISCUSSION
While some patellar tendinopathies evolve favourably with 
traditional conservative treatments (NSAIDs, physiothera-
py/rehabilitation, shock wave therapy, etc.), others remain 
chronic. It is for this reason that a lot of research has been 
carried out to develop or adapt treatments for such rebel 
conditions, among which PRP and HA (13, 28).
Some clinical studies have previously evaluated the effect of 
PRP in the treatment of proximal patellar tendinopathies (6, 
23, 24, 29). Even if this treatment remains controversial in 
the literature, recent systematic reviews have concluded that 
PRP could be recommend (low evidences) as a treatment 
in such indications (8-12). The use of HA in the treatment 
of tendinopathies is even more recent in clinical practice, 
even if pre-clinical studies in the healing process of tendons 
have been reported in the past 20 years (13, 14, 30). Howev-
er, it seems that HA injections have been effective in small 
groups of patients with tendinopathies (13).
The PRP used in this study was a leukocyte-poor PRP with 
a concentration of 850,000 platelets/microliter which is 
usually recommended in other studies (26, 31). To collect 
platelets, an apheresis machine was used to obtain the same 
platelet concentration for each patient (25). Moreover, only 
one intra-tendinous injection was carried out as we demon-
strated that it was not necessary to replicate them (24). HA 
is classically used in cases of osteoarthritis (32). Recently, it 
has been adapted to be used in the treatment of tendinopa-
thies (13). In these cases, HA is concentrated to 2% and also 
contains mannitol which confers anti-inflammatory proper-
ties (13, 33). Two injections were carried out as in previ-
ous studies and also as recommended in these papers (19, 
21, 30). Hyaluronic acid could have the ability to promote 
tendon gliding and reduce adhesion as well as to improve 
the architectural organisation (13).
As PRP needs to be associated with rehabilitation to be 
effective, we added it to our post-injection protocol even 
though it is not an obligation after HA injection. We are 
reminded that all patients had no success with conservative 
management techniques, including physiotherapy, prior to 
inclusion.
In our study, which is the first to compare intra-tendinous 
injections of PRP with those of HA, both under US guid-
ance, we wanted to compare the effects of both treatments 
on chronic patellar tendinopathies with a follow-up after 3 
months to evaluate the medium term effects. We observed 
that both PRP and HA can alleviate the symptoms, espe-
cially pain, of such conditions. As for isokinetic assess-
ment, a significant improvement in quadriceps strength 
was observed after an injection of PRP while no improve-
ment was observed after 2 injections of HA. However, we 
observed that pain decreases during the assessment for the 3 
contraction modes in the HA group. In view of the standard 
deviations of VAS during isokinetic assessment at the end 
of follow-up, even if there is a significant overall improve-
ment, some patients remain in considerable pain even in 
the HA group. HA seems to have a quicker pain-killing 
effect during functional assessments than PRP, which is 
known to be effective only after a minimum of 3 months, 
and that this improvement continues for up to 1 year (8, 
13). Thus, a longer follow-up should be used to evaluate the 
long term evolution of these two treatments, but both treat-
ments can be considered in cases of patellar tendinopathies 
for intermediate terms (3 months), even if there are more 
proof points in the literature for PRP injections. Howev-
er, the correlations showed that the increasing strength in 
C60, C240 and E30 is related to a decrease in pain evaluat-
ed with VAS only with the PRP group. This observation is 
really essential in the rehabilitation of patellar tendinopathy 
which can lead to a loss of quadriceps strength linked to a 
decrease in their use.
Our study presents some limitations: a) we compared 2 
groups with infiltrations of PRP and HA, but we did not 
have a real control group. However, the aim was to evaluate 
outcomes of 1 and 2 infiltrations of PRP, not to compare the 
effect of PRP against a control group; b) as we compared 1 
infiltration of PRP to 2 infiltrations 15 days apart, evalua-
tions of Group 2 took place 2 weeks after those of Group 1. 
However, the evaluation delay after the last infiltration was 
identical for both groups - 6 weeks and 3 months. 
CONCLUSIONS
Both PRP and HA can alleviate the symptoms of proxi-
mal patellar tendinopathy in the medium term. HA can be 
considered as a new treatment for tendinopathies. Howev-
er, only PRP leads to a decrease in pain associated with an 
increase in the strength during isokinetic assessment. Stud-
ies with a more long term follow-up should be carried out.
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